Andrew M. Evens, DO,MBA,MSc

Andrew M Evens DO, MBA, MSc
Deputy Director for Clinical Services, Rutgers Cancer Institute of New Jersey
Associate Vice Chancellor, Clinical Innovation & Data Analytics, Rutgers Health
System Director of Medical Oncology, and Oncology Lead for RWJBarnabas-Rutgers Medical Group, RWJBarnabas Health
Professor of Medicine, Rutgers Robert Wood Johnson Medical School

I am thrilled to be a member of the Rutgers Cancer Institute of New Jersey as the Deputy Director for Clinical Services; System Director of Medical Oncology and Oncology Lead for the Combined Medical Group with RWJBarnabas Health (RWJBH); and Associate Vice Chancellor for Clinical Innovation and Data Analytics, within Rutgers Health at Rutgers University. Rutgers Cancer Institute is one of only 56 cancer centers recognized nationally and New Jersey’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center. Our mission is to deliver comprehensive and compassionate cancer care across the health system with access to worldwide expertise and innovative cancer therapies not available elsewhere in the state.

I completed a fellowship in hematology/oncology at Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center in Chicago, Illinois, where I also remained as a faculty member altogether for 11 years. Most recently, I served as the director of the Cancer Center at Tufts Medical Center in Boston, chief of their division of hematology/oncology, and Professor of Medicine at Tufts University School of Medicine.

My clinical expertise and research interests are focused in the field of lymphoid malignancies, in particular Hodgkin lymphoma and non-Hodgkin lymphoma. Over the past 20 years, I have been the principal investigator of more than 100 cancer clinical trials that have included phase I, II, and III studies, and I help lead several national and global health outcomes and data analytics projects in lymphoma. Collectively, my research has been continuously funded by the National Institutes of Health (NIH) since 2005. This has resulted in 400+ research abstract presentations at national and international cancer symposiums, 230+ manuscripts in peer-reviewed publications, and 40+ book chapters with an emphasis on the prognosis, treatment, and health outcomes of cancer.

Nationally, I am a core member of the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee, and an ad hoc member of additional clinical and scientific committees for the NIH, Cancer Therapy Evaluation Program (CTEP), and the Food and Drug Administration (FDA). I was an associate editor for the British Journal of Haematology for 8 years and now serve as the inaugural editor-in-chief of the gold open-access journal, eJHaem. I am Vice-Chair of the Lymphoma Committee for the ECOG-ACRIN cancer research group; Co-Chair of the Big 10 Cancer Research Consortium lymphoma working group; and a re-elected member and the Chair-elect for the esteemed North American Scientific Advisory Board (SAB) for the Lymphoma Research Foundation that is comprised of 45 world-renowned lymphoma experts. Finally, I help lead a multitude of regional, national, and international educational forums and scientific events.

Rutgers Cancer Institute has a rich history of conducting state-of-the-art and groundbreaking cancer research, and together with RWJBH and Rutgers Health, offers international expertise, multidisciplinary clinical care, leading-edge cancer treatments, and unparalleled resources for cancer patients and their families all close to home. I am honored to be a member of the Rutgers Cancer Institute and a leader of the RWJBH oncology service line working alongside the multitude of outstanding oncology providers providing compassionate and expert cancer care throughout the state of New Jersey and beyond.

Philosophy of Care:

My philosophy of care is patient-centered and highly individualized. It is critical to examine all possible therapeutic options and to identify the most innovative and effective treatment for each individual patient. Furthermore, it is also essential to surround the patient and their family with as many resources as possible (e.g., nursing, nutrition, social services, etc) to help support them throughout their cancer journey. In addition, close collaboration of care with the primary care provider and all other physicians/experts involved in the patients care- working as a cohesive team is important in optimizing outcomes for every patient.

Awards and Honors:

• Jersey's Best, Top Doctors In Cancer Care (2023)
• Annual Honoree, Madeline Fiadini LoRe Foundation Gala (2022)
• Jersey's Best, Top Doctors In Cancer Care (2022)
• Top Doctor, New York Metro Area (2022)
• Ted Marousas Award, Rutgers Business School (2022)
• Jersey's Best, Top Doctors In Cancer Care (2021)
• Board of Trustees, Leukemia & Lymphoma Society, New Jersey Chapter
• Jersey's Best, Top Doctors In Cancer Care (2020)
• Top Doctor, New York Metro Area (2020)
• Re-elected Member, Scientific Advisory Board (SAB) for the Lymphoma Research Foundation (2014 and 2019)
• New Jersey Top Doctor in Cancer Care (2019)
• Grand Marshall, Lymphoma Research Foundation New York Walk (2019)
• Top Doctor, Boston Magazine (2017 and 2018)
• National Co-Chair, North American Educational Forum on Lymphoma, Lymphoma Research Forum (2017 and 2022)
• Chan Soon-Shiong Endowed Scholar in Precision Medicine, Tufts Medical Center (2016)
• Advisory Panel to Vice President Joseph Biden’s “Cancer Moonshot” initiative, Washington, DC (2015)
• Teaching Oncology Attending of the Year, Division of Hematology/Oncology, Northwestern University (2009)
• Excellence in Teaching Award, Department of Medicine, Northwestern University (2008-9)
• Compassionate Care Award, The Woman’s Board of Northwestern Memorial Hospital (2005)
• Translational Research Award, ECOG’s Young Investigators’ Clinical Scientist Symposium (2002)
• Compassion Care Awards, Lutheran General Hospital (1996-2000)
• Intern of the Year, Lutheran General Hospital (1996-1997)
• Sigma Sigma Phi National Osteopathic Honor Society (1994)
• Bill Bradley Academic All-American, NCAA Division II Basketball (1989)

Press Items:

Researchers from Rutgers Cancer Institute evaluated the frequency of SARS-CoV-2 RNA on various environmental surfaces and found extremely low detection of SARS-CoV-2 on across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor. Learn more

Rutgers Cancer Institute announced the publication of research that has identified and validated the novel Burkitt Lymphoma International Prognostic Index (BL-IPI) in patients with this rare, high-grade B-cell lymphoma that is often studied in trials with small sample sizes. Read more

In recognition of Leukemia and Lymphoma Awareness Month, Rutgers Cancer Institute of New Jersey hosted a Twitter chat to discuss the basics of blood cancers, treatment amid COVID-19, and ongoing research in the field. Read the recap here.

Dr. Evens shares more about the new HoLISTIC consortium that contributed to the basis of Hodgkin lymphoma work being presented at the American Society for Clinical Oncology (ASCO) Annual Meeting being held virtually this year. Read more

Dr. Evens discusses his treatment of newly diagnosed classical Hodgkin Lymphoma in this blog. Read more

Dr. Evens recaps his presentation from the ASH Annual Hematologic Malignancies Conference where he spoke about how he treats newly‑diagnosed, classical Hodgkin lymphoma. Watch here

In The News

Dr. Andrew Evens discusses the new prognostic indicator for Burkitt lymphoma in a recent interview with Check Rare. Learn more

Useful Links:

Leukemia/Lymphoma/Hematologic Malignancies Program

Blood and Marrow Transplant Program

East Tower Location

Cardio-Oncology Program

Dr. Evens Research Profile